Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature

Jordan E. Buckley; Laura N. Landis; Ronald P. Rapini

doi:10.1016/j.jdin.2022.01.009

Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature

Jordan E. Buckley, Laura N. Landis, Ronald P. Rapini

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation.

Original language	English (US)
Pages (from-to)	164-168
Number of pages	5
Journal	JAAD International
Volume	7
DOIs	https://doi.org/10.1016/j.jdin.2022.01.009
State	Published - Jun 2022
Externally published	Yes

Keywords

coronavirus
COVID-19
dermatology
Moderna
mRNA vaccine
Pfizer
pityriasis rosea
pityriasis rosea–like eruption
PR
PR-LE
vaccine

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jdin.2022.01.009

Cite this

@article{8194b9d067974f8999c217093218e88d,

title = "Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature",

abstract = "A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation.",

keywords = "coronavirus, COVID-19, dermatology, Moderna, mRNA vaccine, Pfizer, pityriasis rosea, pityriasis rosea–like eruption, PR, PR-LE, vaccine",

author = "Buckley, {Jordan E.} and Landis, {Laura N.} and Rapini, {Ronald P.}",

note = "Publisher Copyright: {\textcopyright} 2022 American Academy of Dermatology, Inc.",

year = "2022",

month = jun,

doi = "10.1016/j.jdin.2022.01.009",

language = "English (US)",

volume = "7",

pages = "164--168",

journal = "JAAD International",

issn = "2666-3287",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination

T2 - A case report and review of the literature

AU - Buckley, Jordan E.

AU - Landis, Laura N.

AU - Rapini, Ronald P.

PY - 2022/6

Y1 - 2022/6

N2 - A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation.

AB - A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5.6 weeks. It is important for physicians to be aware of this self-limited reaction so they can reassure and appropriately counsel patients that it is safe to receive subsequent vaccine doses despite the cutaneous eruption. Additionally, differences in incidence of this reaction after Pfizer and Moderna vaccination may suggest a differing host immune response incited by these vaccines which warrants further investigation.

KW - coronavirus

KW - COVID-19

KW - dermatology

KW - Moderna

KW - mRNA vaccine

KW - Pfizer

KW - pityriasis rosea

KW - pityriasis rosea–like eruption

KW - PR

KW - PR-LE

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85130888446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130888446&partnerID=8YFLogxK

U2 - 10.1016/j.jdin.2022.01.009

DO - 10.1016/j.jdin.2022.01.009

M3 - Article

C2 - 35156062

AN - SCOPUS:85130888446

SN - 2666-3287

VL - 7

SP - 164

EP - 168

JO - JAAD International

JF - JAAD International

ER -

Pityriasis rosea–like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this